In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 710 ( 2023-08-23)
Abstract:
Although immune checkpoint inhibitors (ICI) has been beneficial for many patients, 40% of patients still fail to respond. To investigate this, Bennion et al . evaluated Fcγ Receptor IIB (FcγRIIB), an inhibitory receptor that has recently been found on activated CD8 + T cells. The authors demonstrated that the Fc portion of the anti–programmed death 1 could bind to FcγRIIB on activated CD8 + & nbsp; T cells in mice and reduce efficacy of immunotherapy, which was abrogated by adding an antibody against FcyRIIB to treatment. These results elucidate an unappreciated mechanism of FcγRIIB-mediated, cell-autonomous suppression, suggesting altering the Fc portion of these antibodies could better improve efficacy across patients. —Dorothy Hallberg
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.add1868
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
detail.hit.zdb_id:
2518839-2
detail.hit.zdb_id:
2518854-9
Permalink